Zoetis Inc. (NYSE:ZTS) Shares Bought by Perennial Investment Advisors LLC

Perennial Investment Advisors LLC lifted its stake in shares of Zoetis Inc. (NYSE:ZTSGet Rating) by 10.5% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,065 shares of the company’s stock after buying an additional 101 shares during the quarter. Perennial Investment Advisors LLC’s holdings in Zoetis were worth $200,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Wade G W & Inc. grew its stake in Zoetis by 0.3% in the 4th quarter. Wade G W & Inc. now owns 17,654 shares of the company’s stock valued at $4,308,000 after buying an additional 53 shares during the last quarter. Arete Wealth Advisors LLC increased its stake in shares of Zoetis by 2.5% in the fourth quarter. Arete Wealth Advisors LLC now owns 2,200 shares of the company’s stock worth $519,000 after purchasing an additional 54 shares during the period. Shorepoint Capital Partners LLC lifted its position in shares of Zoetis by 0.9% during the 4th quarter. Shorepoint Capital Partners LLC now owns 6,273 shares of the company’s stock worth $1,531,000 after purchasing an additional 54 shares during the last quarter. Evoke Wealth LLC boosted its stake in Zoetis by 1.8% during the 4th quarter. Evoke Wealth LLC now owns 3,163 shares of the company’s stock valued at $772,000 after purchasing an additional 57 shares during the period. Finally, Bell Investment Advisors Inc grew its holdings in Zoetis by 17.5% in the 4th quarter. Bell Investment Advisors Inc now owns 382 shares of the company’s stock valued at $93,000 after buying an additional 57 shares during the last quarter. 90.73% of the stock is owned by institutional investors and hedge funds.

Zoetis Stock Up 0.2 %

Shares of ZTS opened at $174.61 on Friday. The company has a market capitalization of $82.18 billion, a P/E ratio of 39.59, a PEG ratio of 2.96 and a beta of 0.73. Zoetis Inc. has a one year low of $154.18 and a one year high of $249.27. The business’s 50 day simple moving average is $171.80 and its 200-day simple moving average is $181.35. The company has a debt-to-equity ratio of 1.12, a current ratio of 2.25 and a quick ratio of 1.58.

Zoetis (NYSE:ZTSGet Rating) last issued its quarterly earnings data on Thursday, August 4th. The company reported $1.20 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.22 by ($0.02). The business had revenue of $2.10 billion during the quarter, compared to the consensus estimate of $2.03 billion. Zoetis had a net margin of 26.14% and a return on equity of 48.90%. The company’s revenue for the quarter was up 7.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.19 EPS. As a group, sell-side analysts predict that Zoetis Inc. will post 5.03 EPS for the current fiscal year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 1st. Stockholders of record on Thursday, July 21st will be given a dividend of $0.325 per share. The ex-dividend date of this dividend is Wednesday, July 20th. This represents a $1.30 dividend on an annualized basis and a dividend yield of 0.74%. Zoetis’s payout ratio is 29.48%.

Insider Activity

In other Zoetis news, Director Willie M. Reed sold 1,855 shares of the stock in a transaction on Friday, June 10th. The stock was sold at an average price of $162.31, for a total value of $301,085.05. Following the transaction, the director now directly owns 6,782 shares in the company, valued at approximately $1,100,786.42. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, EVP Roxanne Lagano sold 4,334 shares of the stock in a transaction that occurred on Monday, June 27th. The shares were sold at an average price of $175.00, for a total value of $758,450.00. Following the transaction, the executive vice president now directly owns 23,687 shares in the company, valued at $4,145,225. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Willie M. Reed sold 1,855 shares of the firm’s stock in a transaction that occurred on Friday, June 10th. The shares were sold at an average price of $162.31, for a total transaction of $301,085.05. Following the completion of the transaction, the director now directly owns 6,782 shares in the company, valued at $1,100,786.42. The disclosure for this sale can be found here. Insiders have sold 18,356 shares of company stock valued at $3,250,158 over the last three months. 0.12% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on ZTS. Stifel Nicolaus reduced their price objective on Zoetis from $275.00 to $225.00 and set a “buy” rating for the company in a research report on Friday, June 24th. Piper Sandler assumed coverage on shares of Zoetis in a research report on Monday, July 11th. They issued an “overweight” rating and a $205.00 price target on the stock. William Blair restated an “outperform” rating on shares of Zoetis in a research report on Friday. The Goldman Sachs Group lowered their target price on shares of Zoetis from $208.00 to $202.00 and set a “buy” rating on the stock in a research note on Thursday, July 21st. Finally, StockNews.com cut shares of Zoetis from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, April 26th. One analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $224.88.

About Zoetis

(Get Rating)

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

See Also

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTSGet Rating).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.